您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Eprenetapopt(APR246 PRIMA-1MET)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Eprenetapopt(APR246 PRIMA-1MET)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Eprenetapopt(APR246 PRIMA-1MET)图片
CAS NO:5291-32-7
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)199.25
FormulaC10H17NO3
CAS No.5291-32-7 (PRIMA-1MET; APR-246);
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: >10mg/mL
Water: <1 mg/mL
Ethanol: <1 mg/mL
SMILES O=C1C(COC)(CO)N2CCC1CC2
Synonyms APR-246; Eprenetapopt; APR246; APR 246; PRIMA-1Met.
实验参考方法
In Vitro

In vitro activity: APR-246 (Eprenetapopt; PRIMA-1MET) is the first clinical-stage compound that reactivates mutant p53 and induces apoptosis. APR-246 is a prodrug that is converted to the active compound methylene quinuclidinone (MQ), a Michael acceptor that binds to cysteine residues in mutant p53 and restores its wild-type conformation. APR-246 completely restores the cisplatin and doxorubicin sensitivity to p53-mutant drug-resistant ovarian cancer cells. It not only reactivates p53 but also decreases intracellular glutathione levels in a dose-dependent manner. APR-246 can trigger apoptosis in a p53-independent manner by inducing ROS and endoplasmic reticulum (ER) stress and by inhibiting thioredoxin reductase 1 (TrxR1). It was also reported that APR-246 induces cell death in myeloma cells independently of p53 status by impairing the GSH/ROS balance. PRIMA-1Met/APR-246 efficiently inhibited the growth of the SCLC cell lines expressing mutant p53 in vitro and induced apoptosis, associated with increased fraction of cells with fragmented DNA, caspase-3 activation, PARP cleavage, Bax and Noxa upregulation and Bcl-2 downregulation in the cells.


Kinase Assay: Cells are plated in six-well plates at a density of 15 000 cells per cm2. Next day, cells are treated with different concentrations of APR-246 (0, 25, 50, 75 and 100 μM) and harvested after 4, 12 and 24 h. The cells are lysed, and the clarified supernatants are used for either analysis of TrxR enzymatic activities or western blot. Total protein concentrations are determined with a Bradford reagent kit. Cellular TrxR activity is measured using an adapted Trx-dependent end point insulin reduction assay for microwell plates.


Cell Assay: OVCAR-3 cells were plated at a density of 75 000 cells per well in 3 ml of medium in 12-well plates. Next day, 2.5 ml medium was removed and cells were treated with cisplatin or APR-246 or in combination for 20 h. Next day, cells were harvested by trypsinization, washed twice and cells were stained with Annexin V and propidium iodine (PI). After staining, the samples were analyzed by LSRII flow cytometer.

In VivoAPR-246 showed a good safety profile in a Phase I/II clinical dose-finding study on hematological malignancies and prostate cancer and both clinical and p53-dependent biological responses were observed. In animal studies, APR-246 is well tolerated. Single treatment with APR-246 inhibits tumor growth by 21% in mice bearing the aggressively growing A2780-CP20 tumor xenografts
Animal modelCD-1 Nu/Nu mice
Formulation & DosageDissolved in PBS; 400 mg/kg/day; i.v. injection
ReferencesCell Death Dis. 2015 Jun 18;6:e1794; Clin Cancer Res. 2011 May 1;17(9):2830-41.
生物活性


Inhibition of TrxR1 in vitro by APR-246. Cell Death Dis. 2013 Oct 24;4:e881.


siRNA knockdown of TrxR1 inhibits APR-246-induced cell death. Cell Death Dis. 2013 Oct 24;4:e881.



siRNA knockdown of TrxR1 inhibits generation of ROS induced by treatment with APR-246. Cell Death Dis. 2013 Oct 24;4:e881.


Inhibition of TrxR1 activity in living cells. Cell Death Dis. 2013 Oct 24;4:e881.